LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

43.05 1.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

43.05

Max

43.05

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+27.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-25M 3.2B
Eelmine avamishind	41.4
Eelmine sulgemishind	43.05

Uudiste sentiment

By Acuity

25%

75%

49 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. veebr 2026, 17:37 UTC

Omandamised, ülevõtmised, äriostud

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20. veebr 2026, 16:18 UTC

Suurimad hinnamuutused turgudel

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20. veebr 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. veebr 2026, 22:12 UTC

Tulu

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. veebr 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. veebr 2026, 21:23 UTC

Tulu

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. veebr 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. veebr 2026, 21:01 UTC

Omandamised, ülevõtmised, äriostud

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. veebr 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20. veebr 2026, 20:17 UTC

Market Talk

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20. veebr 2026, 20:11 UTC

Market Talk

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20. veebr 2026, 19:59 UTC

Market Talk

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20. veebr 2026, 19:58 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20. veebr 2026, 19:49 UTC

Market Talk

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20. veebr 2026, 19:09 UTC

Market Talk

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20. veebr 2026, 19:00 UTC

Market Talk

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20. veebr 2026, 18:28 UTC

Market Talk

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20. veebr 2026, 18:20 UTC

Market Talk

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20. veebr 2026, 18:05 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. veebr 2026, 18:04 UTC

Market Talk

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20. veebr 2026, 17:38 UTC

Market Talk

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20. veebr 2026, 17:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. veebr 2026, 17:24 UTC

Market Talk

Correction to Treasury Yields Fall Market Talk

20. veebr 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

20. veebr 2026, 16:53 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. veebr 2026, 16:53 UTC

Market Talk

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20. veebr 2026, 16:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. veebr 2026, 16:45 UTC

Market Talk

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20. veebr 2026, 16:40 UTC

Market Talk

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

27.67% tõus

12 kuu keskmine prognoos

Keskmine 55 USD 27.67%

Kõrge 66 USD

Madal 44 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

49 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.